1-(3,4-二甲氧基苯基)哌嗪盐酸盐 | 16015-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3,4-二甲氧基苯基)哌嗪盐酸盐
• 英文名称: 1-(3,4-dimethoxyphenyl)piperazine hydrochloride
• 英文别名: 1-(3,4-dimethoxyphenyl)piperazine;hydrochloride
• CAS: 16015-72-8
• 化学式: C₁₂H₁₈N₂O₂*ClH
• mdl: MFCD00040815
• 分子量: 258.748
• InChiKey: WXLJIVYSDTVIHM-UHFFFAOYSA-N

物化性质

• 熔点：
  230°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.23
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(3,4-二甲氧基苯基)哌嗪盐酸盐 在 potassium iodide 、 potassium carbonate 作用下， 以 丁酮 为溶剂， 生成 1-[2-(3,4-dihydro-1(2H)-benzopyran-4-yl)ethyl]-4-(3,4-dimethoxyphenyl)piperazine dihydrochloride
  参考文献：
  名称：

  Benzopyran derivatives and pharmaceutical compositions containing them

  摘要：

  新的苯并吡喃衍生物的化学式为：##STR1## 其中 R.sub.1 是氢、卤素、羟基、烷氧基、硝基、氨基、烷基磺酰胺基、双(烷基磺酰基)氨基或酰胺基，X 是氮或一个 >CH-基团，R 是一个化学式的基团：##STR2## 其中 A 表示一个单键或亚甲基，或者当 X 是氮时，A 可表示羰基，R.sub.2 和 R.sub.3，它们相同或不同，是氢、卤素、羟基、烷基、烷氧基、硝基、氨基、烷基磺酰胺基、双(烷基磺酰基)氨基、酰胺基、磺酰胺基或氰基，或者当它们相邻时，一起形成一个亚甲二氧基或乙烯二氧基基团，或者 R 是吡啶基或 2(2H)-苯并咪唑基，如果 X 表示 >CH--，而 R' 和 R" 相同且是氢或烷基，它们的异构体形式和混合物，以及它们的酸盐加合物，可用作抗心律失常和抗纤颤剂。

  公开号：

  US04977166A1
• 作为产物：
  描述：

  4-溴黎芦醚 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 甲醇 、 甲苯 为溶剂， 生成 1-(3,4-二甲氧基苯基)哌嗪盐酸盐
  参考文献：
  名称：

  CN116803984

  摘要：

  公开号：

文献信息

• HYDROQUINONE DERIVATIVES
  申请人：——

  公开号：US20010008893A1

  公开（公告）日：2001-07-19

  A hydroquinone derivative useful as an intraocular pressure lowering, anti-hypertensive and radical scavenging agent represented by the following formula 1 wherein B 1 and B 2 in formula (I) are the same or different and at any position on the benzene ring (when W is nitrogen, however, at any other position on the benzene ring) and each denotes a substituent selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkoxyl and carboxyl, and the substituent CH 3 is at position 2 or 3, and W are the same or different and each denotes a nitrogen or carbon atom. R 1 , R 2 , R 3 and R 4 in formula (II) are the same or different and each denotes a substituent selected from the group consisting of hydrogen, lower alkyl and lower alkoxyl, and B 1 and B 2 are as hereinbefore defined, or a pharmacologically acceptable salt thereof.

  一种具有降低眼内压、抗高血压和自由基清除作用的有用氢醌衍生物，由以下式1表示，其中式（I）中的B1和B2相同或不同，并且在苯环上的任何位置（当W为氮时，在苯环上的任何其他位置），每个表示从氢、卤素、羟基、低级烷氧基和羧基组成的组中选择的取代基，并且取代基CH3位于位置2或3，并且W相同或不同，每个表示氮或碳原子。式（II）中的R1、R2、R3和R4相同或不同，每个表示从氢、低级烷基和低级烷氧基组成的组中选择的取代基，并且B1和B2如前所述，或其药理学上可接受的盐。
• Sulfonyl Amino Cyclic Derivatives and Use Thereof
  申请人：Swinnen Dominique

  公开号：US20080194520A1

  公开（公告）日：2008-08-14

  The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

  本发明涉及公式（I）的衍生物及其在特定疾病的治疗和/或预防中的应用，特别是在自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、癌症、呼吸系统疾病和纤维化等方面的应用，包括多发性硬化症、关节炎、肺气肿、慢性阻塞性肺疾病、肝纤维化和肺纤维化。
• Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
  申请人：Balestra Michael

  公开号：US20090069340A1

  公开（公告）日：2009-03-12

  Compounds of Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.

  公式（I）的化合物，其中R1，R2，R3，R4，R5，R6，X和n的定义如描述中的公式（I），制备该化合物的过程以及用于制备的新中间体，含有该化合物的制药组合物以及在治疗或预防与谷氨酸功能障碍有关的神经系统和精神障碍中使用该化合物。
• Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1<i>H</i>-tetrazols as novel microtubule destabilizers
  作者：Chao Wang、Yuelin Li、Zi Liu、Zeyu Wang、Zihan Liu、Shuai Man、Yujing Zhang、Kai Bao、Yingliang Wu、Qi Guan、Daiying Zuo、Weige Zhang

  DOI：10.1080/14756366.2020.1759582

  日期：2021.1.1

  A series of 1-aryl-5-(4-arylpiperazine-1-carbonyl)-1H-tetrazols as microtubule destabilizers were designed, synthesised and evaluated for anticancer activity. Based on bioisosterism, we introduced the tetrazole moiety containing the hydrogen-bond acceptors as B-ring of XRP44X analogues. The key intermediates ethyl 1-aryl-1H-tetrazole-5-carboxylates 10 can be simply and efficiently prepared via a microwave-assisted continuous operation process. Among the compounds synthesised, compound 6-31 showed noteworthy potency against SGC-7901, A549 and HeLa cell lines. In mechanism studies, compound 6-31 inhibited tubulin polymerisation and disorganised microtubule in SGC-7901 cells by binding to tubulin. Moreover, compound 6-31 arrested SGC-7901cells in G2/M phase. This study provided a new perspective for development of antitumor agents that target tubulin.
• Indolebutylamines as Selective 5-HT_1A Agonists
  作者：Timo Heinrich、Henning Böttcher、Gerd D. Bartoszyk、Hartmut E. Greiner、Christoph A. Seyfried、Christoph van Amsterdam

  DOI：10.1021/jm040792y

  日期：2004.9.1

  A series of new 1-[4-(indol-3-yl)butyl]-4-arylpiperazines was prepared to identify highly selective and potent 5-HT1A agonists as potential pharmacological tools in studies of mood disorders. The combination of structural elements (indole-alkyl-amine and aryl-piperazine) known to introduce 5-HT1A receptor affinity and the proper selection of substituents (R on the indole moiety and R' on the aryl moiety) led to compounds with high receptor specificity and affinity. In particular, the introduction of the methyl ether or the unsubstituted carboxamide as substituents in position 5 of the indole (R) guaranteed serotonergic 5-HT1A affinity compared to the unsubstituted analogue. Para-substituted arylpiperazines (R') decreased dopaminergic D-2 binding and increased selectivity for the 5-HT1A receptor. Agonistic 5-HT1A receptor activity was confirmed in vivo in the ultrasonic vocalization test, and the results suggest that the introduction of the carboxamide residue leads to better bioavailability than the corresponding methyl ether. 3-4-[4-(4-Carbamoylphenyl)piperazin-1-yl}butyl}-1H-indole-5-carboxamide 54 was identified as a highly selective 5-HT1A receptor agonist [GTPgammaS, ED50 = 4.7 nM] with nanomolar 5-HT1A affinity [IC50 = 0.9 nM] and selectivity [D-2, IC50 > 850 nM]. 3-4-[4-(4-Methoxyphenyl)piperazin-1-yl]butyl}-1H-indole-5-carboxamide 45 is one of the most potent and selective 5-HT1A agonists known [5-HT1A, IC50 = 0.09 nM; D-2, IC50 = 140 nM].